T. Rowe Price Associates’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $647K | Buy |
48,415
+5,188
| +12% | +$69.3K | ﹤0.01% | 2186 |
|
|
2025
Q1 | $441K | Sell |
43,227
-866,480
| -95% | -$8.84M | ﹤0.01% | 2297 |
|
|
2024
Q4 | $14.4M | Sell |
909,707
-604,798
| -40% | -$9.57M | ﹤0.01% | 1055 |
|
|
2024
Q3 | $87.9M | Buy |
1,514,505
+326,595
| +27% | +$19M | 0.01% | 594 |
|
|
2024
Q2 | $54.3M | Sell |
1,187,910
-30,594
| -3% | -$1.4M | 0.01% | 698 |
|
|
2024
Q1 | $80.7M | Buy |
1,218,504
+176,803
| +17% | +$11.7M | 0.01% | 595 |
|
|
2023
Q4 | $41.4M | Sell |
1,041,701
-225,531
| -18% | -$8.97M | 0.01% | 759 |
|
|
2023
Q3 | $40.4M | Sell |
1,267,232
-3,129
| -0.2% | -$99.8K | 0.01% | 744 |
|
|
2023
Q2 | $51M | Buy |
1,270,361
+117,845
| +10% | +$4.74M | 0.01% | 698 |
|
|
2023
Q1 | $49.2M | Buy |
1,152,516
+531,327
| +86% | +$22.7M | 0.01% | 689 |
|
|
2022
Q4 | $29.8M | Buy |
621,189
+611,459
| +6,284% | +$29.4M | ﹤0.01% | 810 |
|
|
2022
Q3 | $367K | Buy |
+9,730
| New | +$367K | ﹤0.01% | 2279 |
|
|
2022
Q2 | – | Sell |
-4,505
| Closed | -$245K | – | 2983 |
|
|
2022
Q1 | $245K | Sell |
4,505
-2,062
| -31% | -$112K | ﹤0.01% | 2628 |
|
|
2021
Q4 | $384K | Buy |
+6,567
| New | +$384K | ﹤0.01% | 2504 |
|